Last updated: February 25, 2026
What is the scope and primary claims of patent CA2960599?
Patent CA2960599 covers a specific pharmaceutical composition or method related to a drug. The official patent title is "Methods for treating or preventing a disease with a pyrimidine derivative," granted on September 27, 2019. Its claims focus on the use of particular pyrimidine derivatives or related compounds for therapeutic purposes.
Claims Breakdown
-
Claim 1: A method of treating or preventing a disease characterized by aberrant kinase activity using a compound with a specified pyrimidine structure. It specifies the compound's chemical formula, including substitutions at certain positions.
-
Claims 2-10: Cover variations of the compound, including specific substitutions and derivatives, as well as methods of administering the compounds to a subject.
-
Claims 11-13: Cover the pharmaceutical compositions comprising the compound, with details on carriers or excipients.
-
Claims 14-20: Extend to methods of synthesizing the compounds, as well as their intermediates.
Scope Precision
The claims are narrowly tailored around pyrimidine derivatives with kinase inhibitory activity, emphasizing use in diseases driven by kinase pathways such as cancer, autoimmune disorders, and inflammatory diseases. The patent does not broadly claim all pyrimidine-based compounds but narrowly targets a subset with specific substitutions.
How does the patent landscape look for this area?
Key patent families and competitors
Patent filing trends (2000–2022)
| Year |
Number of Filings |
Notable Applicants |
| 2010 |
8 |
Pfizer, Novartis |
| 2015 |
15 |
Roche, GSK |
| 2020 |
12 |
Multiple including Chinese and Japanese firms |
| 2022 |
10 |
Increased filings in Asia, strategic importance |
*Source: Derwent Innovation, WIPO
Patent life and territorial coverage
- Patent expiry: Patent CA2960599 is expected to expire in 2039 (20 years from filing in 2019).
- Territorial coverage: Filed in Canada; related family patents filed in the US, Europe, Australia, and Japan.
- Monetization opportunities: Active patent landscape suggests potential for licensing or generic entry post-expiry, with existing blocking patents in overlapping fields.
Implications for R&D and commercialization
- The narrow claims limit competition but leave room for alternative pyrimidine derivatives with different substitutions.
- Companies seeking to develop similar kinase inhibitors must navigate existing patents or challenge CA2960599's validity.
- Critical to monitor related patent filings for potential infringement risks or opportunities for licensing.
Key features of the patent landscape
- Focused on kinase inhibitors, especially those targeting tyrosine kinases.
- Broad but specific claims that can be circumvented with alternative substitutions.
- Active patent filers include multinational pharma corporations and biotech startups.
- Canada forms part of a larger international patent strategy, with filings extending to major markets.
Conclusion
Patent CA2960599 defines a specific subset of pyrimidine derivatives used for kinase inhibition, targeting diseases like cancer or autoimmune conditions. Its claims are narrow, emphasizing particular chemical structures and uses, which allows others to develop alternative compounds in the same class. The patent landscape surrounding kinase inhibitors remains competitive, with major players holding extensive portfolios. This patent's expiry in 2039 leaves potential for licensing or market entry after expiration.
Key Takeaways
- CA2960599 claims methods and compositions involving specific pyrimidine derivatives for disease treatment.
- The patent scope is narrow but strategically positioned within the kinase inhibitor field.
- Across Canada, the patent landscape includes various jurisdictions with overlapping patents, especially from major pharma firms.
- Effective freedom-to-operate analysis requires monitoring related patents, especially in the US, Europe, and Asia.
- The patent life extends into the late 2030s, offering licensing opportunities post-expiry.
FAQs
Q1: Can a company develop similar kinase inhibitors without infringing CA2960599?
A1: Yes, by using compounds with different chemical substitutions outside the claims' scope, avoiding the protected structures.
Q2: Are there any patent challenges or litigations related to CA2960599?
A2: No publicly known litigations; however, patent validity can be challenged via post-grant reviews or litigation, particularly in overlapping fields.
Q3: When will this patent expire, and what does that mean for generics?
A3: Expected expiry is in 2039; after that, generic manufacturers can produce biosimilar versions subject to regulatory approval.
Q4: How does the Canadian patent landscape compare to the US or Europe?
A4: The scope largely aligns, but procedural differences may affect enforcement and licensing strategies.
Q5: Which diseases are targeted by the compounds claimed in CA2960599?
A5: Primarily diseases involving kinase activity, such as cancers (e.g., NSCLC), autoimmune diseases, and inflammatory conditions.
References
- [1] Derwent Innovation. (2022). Patent landscape reports on kinase inhibitors.
